New hope for kids with resistant tumors: drug combo enters safety trial

NCT ID NCT06104488

First seen Feb 25, 2026 · Last updated May 05, 2026 · Updated 11 times

Summary

This early-phase study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with solid tumors that have returned or not responded to treatment. The main goal is to find a safe dose with manageable side effects. The drugs target specific genetic changes in the tumors to help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Healthcare of Atlanta (Data Collection Only)

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.